Gene · 2348
Papers3,253
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
181 to 200 of 3,253
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Recent therapeutic advances in gynecologic oncology: evolving roles of immunotherapy, antibody-drug conjugates, and clinical trial innovations. | Front Oncol | 2025 | 41626151 | PubTator, text mining | PubMed |
| Novel fully human IgG1 targeting folate receptor α demonstrates antitumor efficacy driven by avidity rather than monovalent binding affinity. | Sci Rep | 2025 | 41476100 | PubTator, text mining | PubMed |
| Molecularly Built Ligands Degrade Membrane Receptors via Enhancing Their Accumulation in Lysosomes. | ACS Cent Sci | 2025 | 41473803 | PubTator, text mining | PubMed |
| Evaluation of folate receptor-alpha and other surface markers as potential targets for radionuclide therapy of ovarian cancer. | EJNMMI Res | 2025 | 41466165 | PubTator, text mining | PubMed |
| Near-infrared photoimmunotherapy for effective elimination of ovarian cancer cells by inducing immunogenic cell death. | Mol Ther Oncol | 2025 | 41362788 | PubTator, text mining | PubMed |
| Understanding the Chemical Characteristics of Payloads and the Expression of Tumor-Associated Antigens of ADCs in Clinical Development. | ACS Omega | 2025 | 41322509 | PubTator, text mining | PubMed |
| In silico design of a multi-epitope vaccine against the triple negative breast cancer. | Sci Rep | 2025 | 41309872 | PubTator, text mining | PubMed |
| Results of the First Folate Receptor Alpha Testing Trial by the German Quality Assurance Initiative in Pathology (QuIP®). | Cancers (Basel) | 2025 | 41301065 | PubTator, text mining | PubMed |
| Real-world insights into the prevalence and prognostic significance of trophoblast cell-surface antigen 2 and folate receptor alpha in uterine carcinosarcoma. | BMC Cancer | 2025 | 41286743 | PubTator, text mining | PubMed |
| Autophagy disruption primes CAR-T cell metabolism for sustained rejection of ovarian tumors. | bioRxiv | 2025 | 41279553 | PubTator, text mining | PubMed |
| FOLR1-targeted Actinium-225-based Alpha-particle Therapy Eliminates Ovarian Cancer. | bioRxiv | 2025 | 41279140 | PubTator, text mining | PubMed |
| Maternal Folate Receptor Alpha Autoantibodies and Increased Fetal Nuchal Translucency as Potential Early Markers of Autism Spectrum Disorder. | Brain Behav | 2025 | 41272990 | PubTator, text mining | PubMed |
| Glutathione-Responsive Folate-Targeted Prodrugs: Tumor-Specific PD-L1 and CD47 Blockade. | Molecules | 2025 | 41226252 | PubTator, text mining | PubMed |
| Prognostic implications of HER2 in ovarian cancer: Associations with homologous recombination deficiency and folate receptor alpha expression. | Gynecol Oncol | 2025 | 41192265 | PubTator, text mining | PubMed |
| [Expert consensus on folate receptor α immunohistochemical testing in ovarian cancer and its clinical applications (2025 version)]. | Zhonghua Bing Li Xue Za Zhi | 2025 | 41183813 | PubTator, text mining | PubMed |
Betulinic Acid Self-Assembled Nanodelivery System Attenuates Osteoarthritis by Dually Modulating Macrophage Polarization and Macrophage-Chondrocyte Crosstalk via Disruption of the GSK3β/NF-κB/CCL20 Axis. | Small | 2025 | 41146595 | PubTator, text mining | PubMed |
| A dual-targeting peptide-drug conjugate based on CXCR4 and FOLR1 inhibits triple-negative breast cancer. | Acta Pharm Sin B | 2025 | 41132836 | PubTator, text mining | PubMed |
| A Case of Cerebral Folate Deficiency due to FOLR1 Mutation in a 10-Year-Old Girl: Clinical Presentation and Treatment Outcomes. | Clin Case Rep | 2025 | 41132636 | PubTator, text mining | PubMed |
| An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer. | Cancer Res | 2025 | 41128663 | PubTator, text mining | PubMed |
| Development of Dual-Receptor Lysosome-Targeting Chimeras for Protein Degradation. | J Am Chem Soc | 2025 | 41127901 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2348/papers?page=10